In 2015, Fankhauser et al. first indicated programmed death receptor ligand 1 (PD-L1) as a promising therapeutic target in TGCTs, demonstrating its immunoexpression in tumor and stromal cells [15]. This evidence concerns the gene CD274 and neoplasm.